Conditions: Rheumatoid Arthritis Interstitial Pneumonia
Keywords: Rheumatoid Arthritis Interstitial Pneumonia Rheumatology Rituximab
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
This study will examine the course of patients with progressive rheumatoid arthritis associated interstitial lung disease (RA-ILD) treated with rituximab for safety and progression-free survival at 48 weeks. Safety of rituximab therapy in this disease will be assessed through patient history, physical exams and laboratory parameters.

* Twelve male/or female patient with RA-associated lung disease (6 of each nonspecific interstitial pneumonia (NSIP) and usual interstitial pneumonia (UIP) histological subtype) will be enrolled
* The study involves 12 visits over 48 weeks
* Rituximab will be administered intravenously at Day 1 and Day 15 with repeat dosing at six months.

Detailed description:

Arms:
arm 1: open label, all subjects will receive rituximab

Interventions: intervention 1: Rituximab
Intervention descriptions: intervention 1: Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.

Protocol document: